Search research articles
Contact Us
Filters
Showing results (391-400 of 504) with videos related to
Page
of 51
Sort By:
JCI Insight
|
February 17, 2026
Deletion 9p drives B-ALL through the heterozygous inactivation of Pax5 and Cd72 in pre-leukemic cells
Belén Ruiz-Corzo, Ana Casado-García, Ninad Oak, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
February 10, 2019
Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
Peter Valent, Cem Akin, Patrizia Bonadonna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2019
MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis
Mohamad Jawhar, Juliana Schwaab, Iván Álvarez-Twose, et al.
American Journal of Hematology
|
September 12, 2025
Tissue-Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts
Peter Valent, Johann Wojta, Petri T Kovanen, et al.
Blood
|
December 4, 2023
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
Camila Guerrero, Noemi Puig, María-Teresa Cedena, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2025
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
Qian Shi, Bruno Paiva, Levi D Pederson, et al.
British Journal of Haematology
|
December 9, 2021
Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study
Martijn W C Verbeek, Chiara Buracchi, Anna Laqua, et al.
Frontiers in Immunology
|
April 9, 2020
EuroFlow Standardized Approach to Diagnostic Immunopheneotyping of Severe PID in Newborns and Young Children
Tomas Kalina, Marina Bakardjieva, Maartje Blom, et al.
Cancers
|
July 9, 2022
Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome
Elen Oliveira, Elaine S Costa, Juana Ciudad, et al.
Leukemia Research
|
November 25, 2015
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia
María-Belén Vidriales, Estefanía Pérez-López, Carlota Pegenaute, et al.
Page
of 51
Search research articles
Search
Showing results (391-400 of 504) with videos related to
Sort By:
Page
of 51
JCI Insight
|
February 17, 2026
Deletion 9p drives B-ALL through the heterozygous inactivation of Pax5 and Cd72 in pre-leukemic cells
Belén Ruiz-Corzo, Ana Casado-García, Ninad Oak, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
February 10, 2019
Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
Peter Valent, Cem Akin, Patrizia Bonadonna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2019
MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis
Mohamad Jawhar, Juliana Schwaab, Iván Álvarez-Twose, et al.
American Journal of Hematology
|
September 12, 2025
Tissue-Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts
Peter Valent, Johann Wojta, Petri T Kovanen, et al.
Blood
|
December 4, 2023
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
Camila Guerrero, Noemi Puig, María-Teresa Cedena, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2025
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
Qian Shi, Bruno Paiva, Levi D Pederson, et al.
British Journal of Haematology
|
December 9, 2021
Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study
Martijn W C Verbeek, Chiara Buracchi, Anna Laqua, et al.
Frontiers in Immunology
|
April 9, 2020
EuroFlow Standardized Approach to Diagnostic Immunopheneotyping of Severe PID in Newborns and Young Children
Tomas Kalina, Marina Bakardjieva, Maartje Blom, et al.
Cancers
|
July 9, 2022
Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome
Elen Oliveira, Elaine S Costa, Juana Ciudad, et al.
Leukemia Research
|
November 25, 2015
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia
María-Belén Vidriales, Estefanía Pérez-López, Carlota Pegenaute, et al.
Page
of 51